Next Article in Journal
Antioxidants and Cardiovascular Risk Factors
Previous Article in Journal
The Developmental Trajectory of Self-Injurious Behaviours in Individuals with Prader Willi Syndrome, Autism Spectrum Disorder and Intellectual Disability
Previous Article in Special Issue
Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy
Open AccessReview

Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future

1
Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR), Singapore 117609, Singapore
2
Lion TCR Private Limited Singapore, Singapore 069113, Singapore
3
Emerging Infectious Diseases (EID) Program, Duke-NUS Graduate Medical School, Singapore 169857, Singapore
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen L. Chan
Diseases 2016, 4(1), 10; https://doi.org/10.3390/diseases4010010
Received: 16 November 2015 / Revised: 28 January 2016 / Accepted: 4 February 2016 / Published: 15 February 2016
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
Cancer immunotherapy using a patient’s own T cells redirected to recognize and kill tumor cells has achieved promising results in metastatic melanoma and leukemia. This technique involves harnessing a patient’s T cells and then delivering a gene that encodes a new T cell receptor (TCR) or a chimeric antigen receptor (CAR) that allow the cells to recognize specific cancer antigens. The prospect of using engineered T cell therapy for persistent viral infections like hepatitis B virus (HBV) and their associated malignancies is promising. We recently tested in a first-in-man clinical trial, the ability of HBV-specific TCR-redirected T cells to target HBsAg-productive hepatocellular carcinoma (HCC) and demonstrated that these redirected T cells recognized HCC cells with HBV–DNA integration [1] We discuss here the possibility to use HBV-specific TCR-redirected T cells targeting hepatitis B viral antigens as a tumor specific antigen in patients with HBV-related HCC, and the potential challenges facing the development of this new immunotherapeutic strategy. View Full-Text
Keywords: immunotherapy; liver tumor; HBV; T cell engineering immunotherapy; liver tumor; HBV; T cell engineering
Show Figures

Figure 1

MDPI and ACS Style

Koh, S.; Tan, A.T.; Li, L.; Bertoletti, A. Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future. Diseases 2016, 4, 10.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop